Core Insights - NeuroPace, Inc. will host an Investor Day on January 28, 2025, in New York City to discuss its vision for RNS technology and future plans [1][2] - The event will feature management presentations on recent results, market strategies, and clinical development for the RNS System, along with guest speakers including clinical experts and an RNS patient [2] Company Overview - NeuroPace is a medical device company based in Mountain View, California, focused on improving the lives of individuals with epilepsy by reducing or eliminating seizures [3] - The RNS System is the first commercially available brain-responsive platform that provides personalized, real-time treatment at the source of seizures, aiming to enhance care for patients with drug-resistant epilepsy [3]

Core Insights - NeuroPace, Inc. has completed enrollment and implant procedures in its feasibility investigational device exemption (IDE) study of the RNS® System for treating Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsy [1][4] - The IDE study aims to evaluate the safety and effectiveness of the RNS System, which has previously shown success in treating medically intractable focal onset seizures in adults [2][3] - The study is funded by a $9.3 million NIH grant and involves 20 patients aged 12 and older with LGS and drug-resistant generalized onset seizures [3] Company Overview - NeuroPace is a commercial-stage medical device company based in Mountain View, California, focused on transforming the lives of individuals with epilepsy through innovative treatments [6] - The RNS® System is the first and only FDA-approved brain-responsive neuromodulation system, designed to provide personalized, real-time treatment by continuously monitoring brain activity [5][6] - The system has demonstrated significant reductions in seizure frequency and improvements in quality of life and cognition without stimulation-related side effects [5] Industry Context - LGS is a debilitating seizure disorder with 85% of affected individuals continuing to experience seizures into adulthood despite aggressive treatment, highlighting the urgent need for innovative treatment options [4] - The RNS System's technology represents a paradigm shift in the treatment of drug-resistant epilepsy, potentially offering better outcomes for a large population suffering from various brain disorders [5][6]

Core Viewpoint - NeuroPace, Inc. (NPCE) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for NeuroPace suggest an improvement in the company's underlying business, likely leading to increased stock prices as investors respond positively [5][8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7][9]. - NeuroPace's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10][11]. Earnings Estimate Revisions - For the fiscal year ending December 2024, NeuroPace is expected to earn -$1 per share, reflecting a year-over-year change of 21.3% [8]. - Over the past three months, the Zacks Consensus Estimate for NeuroPace has increased by 7.6%, indicating a positive trend in earnings expectations [8].

Core Viewpoint - NeuroPace, Inc. (NPCE) shares have increased by 38.8% in the past four weeks, closing at $8.98, with a mean price target of $13.86 indicating a potential upside of 54.3% according to Wall Street analysts [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $4.14, where the lowest estimate suggests a 10.9% decline to $8, while the highest estimate predicts a 100.5% increase to $18 [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [7] Earnings Estimates and Analyst Sentiment - There is growing optimism among analysts about NPCE's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 7.6%, with four estimates moving higher and no negative revisions [10] Zacks Rank and Investment Potential - NPCE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside in the near term [11] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide a useful guide for the direction of price movement [12]

Financial Performance - NeuroPace, Inc. reported a quarterly loss of $0.19 per share, better than the Zacks Consensus Estimate of a loss of $0.26, and an improvement from a loss of $0.28 per share a year ago, representing an earnings surprise of 26.92% [1] - The company posted revenues of $21.06 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 8.95%, and up from $16.43 million in the same quarter last year [2] - Over the last four quarters, NeuroPace has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - NeuroPace shares have declined approximately 29.4% since the beginning of the year, contrasting with the S&P 500's gain of 25.8% [3] - The current Zacks Rank for NeuroPace is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $20.54 million, and for the current fiscal year, it is -$1.08 on revenues of $77.25 million [7] - The estimate revisions trend for NeuroPace is mixed, and future changes in estimates will be closely monitored following the recent earnings report [6][7] Industry Context - NeuroPace operates within the Medical - Instruments industry, which is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of NeuroPace's stock may be influenced by the overall outlook for the industry [8]

NeuroPace, Inc. (NPCE) shares rallied 5.1% in the last trading session to close at $6.35. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 10.1% loss over the past four weeks. NeuroPace recorded a strong price rise on investors' optimism surrounding its impending third-quarter 2024 financial results, which is slated to be released on Nov. 12, 2024, post the closing bell. The Zacks Consensus Estimate for the th ...

MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by a ...

Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Kati ...

MOUNTAIN VIEW, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in the following two healthcare investor conferences in September. Lake Street Big8 Best Ideas Growth Conference - NeuroPace management will host one-on-one meetings with investors at the Lake Street Big8 Best Ideas Growth Conference on Thursday, September 12th in New York. Cantor Global Healthc ...

MOUNTAIN VIEW, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in two healthcare conferences in September. NeuroPace management will host one-on-one meetings with investors at the Wells Fargo 2024 Healthcare Conference, on Wednesday, September 4 in Boston, MA. NeuroPace will also present at the Morgan Stanley 22nd Annual Global Healthcare Conference, which ...